EyePoint

Committed to developing and commercializing innovative therapeutics to improve the lives of people with serious retinal diseases. $EYPT

[EyePoint @EyePointPharma]

When it comes to matters of sight, innovation is our vision.

We’re advancing a potential novel multi-mechanism of action for wet AMD and DME - the largest retinal disease markets where there is a significant need for new therapeutic options.

See more on our programs: https://t.co/6pBh6UV16b

[EyePoint @EyePointPharma]

Tomorrow, members of our management team will join a fireside chat at the 2026 @Jefferies Global Healthcare Conference in New York.

Catch the live webcast here: https://t.co/QHebwulHfC

[EyePoint @EyePointPharma]

Our President & CEO, Jay S. Duker, M.D., was recently featured in @RetinaToday's ‘Then and Now’ spotlight where he discusses the evolution of OCT, a non-invasive retina imaging tool that has transformed eye care over the past 20 years.

Read the full article to see what he thinks is coming next for the technology: https://t.co/RxkpHybcZe

[EyePoint @EyePointPharma]

Discovery is only the beginning.

Watch the video to learn how we’re translating innovation into therapies for patients living with serious retinal diseases in our Northbridge, MA manufacturing facility. ➡️

[EyePoint @EyePointPharma]

Another positive milestone for EyePoint: The Independent Data Safety Monitoring Committee (DSMC) has reaffirmed its support for our Phase 3 wet AMD trials, with LUGANO and LUCIA progressing on schedule.

📈 Topline data expected beginning mid‑2026.

👉 Read more: https://t.co/GfolPoLa2b

[EyePoint @EyePointPharma]

#InvestorNews: #EYPT reports Q1 2026 financial results and highlights recent corporate developments.

See more on our latest pivotal Phase 3 trial progress and recent corporate updates here: https://t.co/arCT2XiXRy

[EyePoint @EyePointPharma]

Our pivotal Phase 3 clinical programs focus on the two largest retinal disease markets: wet AMD and DME. Both are designed by conducting recognized non-inferiority trials for potential global regulatory and commercial success.

Swipe to learn more ➡️

https://t.co/VZ20h7PdyV

[EyePoint @EyePointPharma]

Wet AMD remains a leading cause of vision loss. TKIs, like our lead investigational therapy, have the potential to reduce the need for frequent follow-up visits, while improving patient outcomes.

See the story in @OPH360: 
https://t.co/eqx2OfHfM5

[EyePoint @EyePointPharma]

On this #NationalDoctorsDay, we proudly honor the exceptional principal investigators driving our pivotal Phase 3 clinical programs in wet AMD and DME. https://t.co/Ou7pLgqb28

[EyePoint @EyePointPharma]

Even with current anti-VEGF treatments, many people living with DME still face ongoing vision loss, underscoring the critical need for more durable therapies that also address inflammation.

Learn more about our pivotal Phase 3 program: https://t.co/ltTfGA3lBv

[EyePoint @EyePointPharma]

#InvestorNews: #EYPT reports Q4 and full-year 2025 financial results and highlights recent corporate developments.

See more on our latest pivotal Phase 3 trial progress and recent corporate updates here: https://t.co/HakbPfR3gK

[EyePoint @EyePointPharma]

$EYPT announces first patient in Phase 3 DME clinical trials.

🔎The only sustained release TKI in Phase 3 clinical trials for DME
2️⃣ global, non-inferiority clinical trials, COMO & CAPRI
📈 Topline data expected 2H27

👉 Read more: https://t.co/LChqNkmzHx

[EyePoint @EyePointPharma]

Wet AMD is the leading cause of vision loss and irreversible blindness in people over 50.

This #AMDAwarenessMonth, #EYPT partners with @PBC_savingsight, reinforcing our commitment to improving vision and reducing the treatment burden for patients and caregivers. 

https://t.co/H5adTpE3rf

[EyePoint @EyePointPharma]

$EYPT welcomes Michael Campbell as CCO! With 30+ years of commercial leadership and a proven record of product launches, he will be instrumental as we work to potentially bring the first sustained release TKI to patients.

Read more: https://t.co/vAx4ioENwG

[EyePoint @EyePointPharma]

Team #EYPT kicked off January with impactful meetings nationwide. Thank you to the host organizations for creating spaces to share updates on our #WetAMD and DME clinical progress and learn from the latest innovations shaping the field.

https://t.co/pQIUQ8ToCH

[EyePoint @EyePointPharma]

Our $EYPT team will be in San Francisco next month to present and connect with the investor community at the 44th annual J.P. Morgan Healthcare Conference. #JPM2026

[EyePoint @EyePointPharma]

Thank you to everyone who joined $EYPT at #FLORetina2025! It was an inspiring few days of scientific exchange, meaningful conversations, and collaboration across the retina community.

[EyePoint @EyePointPharma]

Drs. Sridhar, Mammo, and Sarraf are paid consultants of EyePoint; however, the statements made are the opinions of Drs. Sridhar, Mammo, and Sarraf for educational purposes only; their statements are not intended as medical advice or the opinion of EyePoint.

[EyePoint @EyePointPharma]

Now live on your favorite podcast platform, EyePoint presents a three-part series hosted by Jayanth Sridhar, M.D. on New Retina Radio by @eyetubenet.

🎧Tune in to hear from retina specialists on the variations in retinal thickness and how to protect patients’ vision for the long term.

https://t.co/GvLlzLEkot